Immunosuppression With Sirolimus After Solid Organ Transplantation in Children

Marcia L. Buck, Pharm.D., FCCP

Pediatr Pharm. 2006;12(2) 

In This Article


Immunosuppressive therapy is an essential component of the management of children who have received a solid organ transplant. The calcineurin inhibitors, cyclosporine and tacrolimus, have been the primary immunosuppressive agents used in children for the past two decades; however, each is associated with a significant number of adverse effects. Sirolimus was introduced in the United States in 1999 as an adjunct or alternative to traditional therapies.[1,2,3] It has proven to be effective in preventing acute rejection while producing fewer adverse effects, including renal dysfunction. Since 2000, sirolimus has been studied in children after kidney, liver, intestine, and heart transplantation. This issue of Pediatric Pharmacotherapy will review these papers and the potential role of sirolimus in the pediatric transplant population.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: